Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AUDIOCODES LTDAUDC · Entity 26 | Director | September 09, 2026 | September 10, 2026 |
| ORMAT TECHNOLOGIES, INC.ORA · Entity 3743 | Director | June 02, 2026 | June 04, 2026 |
| RADWARE LTDRDWR · Entity 4852 | Director | May 25, 2026 | May 27, 2026 |
| TIGO ENERGY, INC.TYGO · Entity 6903 | Director | May 20, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AUDIOCODES LTD
Report date September 09, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 80,000 |
Reported balance
After 2026-09-09 transaction · row 1
1 source rowRow 1 · 2026-09-09 · Grant · Acquired 10,000 · Balance 80,000 F1: The Reporting Person was granted restricted stock units ("RSUs"), which each represent a contingent right to receive one share of ordinary stock of Audicodes Ltd (the "Company"). The RSUs vest in three equal annual installments, with 3,333 vesting on September 9, 2027 & September 9, 2028 and 3,334 vesting on September 9, 2029, subject to the Reporting Person's continued service to the Company or its subsidiaries through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"), which each represent a contingent right to receive one share of ordinary stock of Audicodes Ltd (the "Company"). The RSUs vest in three equal annual installments, with 3,333 vesting on September 9, 2027 & September 9, 2028 and 3,334 vesting on September 9, 2029, subject to the Reporting Person's continued service to the Company or its subsidiaries through each vesting date.
ORMAT TECHNOLOGIES, INC.
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 899 |
Reported balance
After 2026-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-02 · Grant · Acquired 899 · Balance 899 F1: Each Restricted Stock Unit (RSU) represents the right to receive one share of ORA common stock upon vesting. F2: This portion of RSUs will vest (100%) on June 2, 2027, the one-year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit (RSU) represents the right to receive one share of ORA common stock upon vesting.
F2: This portion of RSUs will vest (100%) on June 2, 2027, the one-year anniversary of the date of grant.
RADWARE LTD
Report date May 25, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock optionsSEC Table II · derivative / convertible security · Conversion / exercise price $29.53 · Expires 2031-07-25 | Direct | 60,000 |
Reported balance
After 2026-05-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-25 · Grant · Acquired 60,000 · Balance 60,000 F1: These stock options vest in equal installments on the first, second and third anniversaries of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: These stock options vest in equal installments on the first, second and third anniversaries of the grant date.
TIGO ENERGY, INC.
Report date May 20, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 497,283 |
Reported balance
After 2026-05-20 transaction · row 1
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 33,068 · Balance 497,283 F1: Represents shares of common stock, par value $0.0001 per share ("Common Stock"), underlying restricted stock units ("RSUs") granted to the reporting person on May 20, 2026 pursuant to the Issuer's 2023 Incentive Plan. The RSUs will vest in full, and an equal number of shares of Common Stock will be deliverable to the reporting person, immediately prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock, par value $0.0001 per share ("Common Stock"), underlying restricted stock units ("RSUs") granted to the reporting person on May 20, 2026 pursuant to the Issuer's 2023 Incentive Plan. The RSUs will vest in full, and an equal number of shares of Common Stock will be deliverable to the reporting person, immediately prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Foamix Pharmaceuticals Ltd.
Report date March 09, 2020 · Filed March 18, 2020
Section 16 reporting ended · disclosed 2020-03-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2020-03-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-03-09 · Disposition to issuer · Disposed 21,147 · Balance 21,212 F1: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2) F2: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement. Row 2 · 2020-03-09 · Disposition to issuer · Disposed 21,212 · Balance 0 F3: Represents Foamix restricted stock unit awards ("Foamix RSUs") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an "Adjusted RSU Award") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $5.88 · Expires 2024-12-29 | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-03-09 · Disposition to issuer · Disposed 27,000 · Balance 0 F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F4: The Options vested over a period of three years from December 29, 2014 (33.3% on each anniversary of such date). |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $4.76 · Expires 2027-07-13 | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-03-09 · Disposition to issuer · Disposed 21,562 · Balance 0 F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F6: The ordinary shares underlying this option vest over a period of four years (25% on July 13, 2017 and 6.25% every three months thereafter) ending July 13, 2021. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $5.06 · Expires 2028-05-08 | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-03-09 · Disposition to issuer · Disposed 24,947 · Balance 0 F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F7: The ordinary shares underlying these options vested over a 12 month period, in equal, quarterly installments, ending May 8, 2019. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.53 · Expires 2030-02-27 | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-03-09 · Disposition to issuer · Disposed 12,719 · Balance 0 F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F8: The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending February 27, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2)
F2: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement.
F3: Represents Foamix restricted stock unit awards ("Foamix RSUs") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an "Adjusted RSU Award") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR.
F4: The Options vested over a period of three years from December 29, 2014 (33.3% on each anniversary of such date).
F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options.
F6: The ordinary shares underlying this option vest over a period of four years (25% on July 13, 2017 and 6.25% every three months thereafter) ending July 13, 2021.
F7: The ordinary shares underlying these options vested over a 12 month period, in equal, quarterly installments, ending May 8, 2019.
F8: The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending February 27, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 03, 2022 Filed Nov 4, 2022 20:30 UTC | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | Exercise / conversionCommon Stock | 1,581 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-026050 · rdgdoc.xml · nonDerivative · entry 1 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2022 Filed Nov 4, 2022 20:30 UTC | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | GrantRestricted Stock Units · Derivative | 623 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-026050 · rdgdoc.xml · derivative · entry 2 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 623 Underlying: Common Stock · 623 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of ORA common stock upon vesting. F2 · derivative.exercise_date: This portion of Restricted Stock Units will vest (100%) on November 2, 2023, the one-year anniversary of the date of grant. F2 · derivative.expiration_date: This portion of Restricted Stock Units will vest (100%) on November 2, 2023, the one-year anniversary of the date of grant. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 21:00 UTC | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $47.46 | $0.00 |
DisclosureSEC source: 0001437749-22-020833 · rdgdoc.xml · derivative · entry 3 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2023-11-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 21:00 UTC | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | SaleCommon Stock | 7,500 | $96.85 | $726,375.00 |
DisclosureSEC source: 0001437749-22-020833 · rdgdoc.xml · nonDerivative · entry 2 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,037 Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 21:00 UTC | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | Exercise / conversionCommon Stock | 7,500 | $47.46 | $355,950.00 |
DisclosureSEC source: 0001437749-22-020833 · rdgdoc.xml · nonDerivative · entry 1 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,537 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 22:56 UTC | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | Exercise / conversionStock Options (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $35.15 | $0.00 |
DisclosureSEC source: 0001437749-22-008091 · rdgdoc.xml · derivative · entry 3 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2023-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 22:56 UTC | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | SaleCommon Stock | 7,500 | $80.85 | $606,375.00 |
DisclosureSEC source: 0001437749-22-008091 · rdgdoc.xml · nonDerivative · entry 2 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,037 Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 22:56 UTC | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | Exercise / conversionCommon Stock | 7,500 | $35.15 | $263,625.00 |
DisclosureSEC source: 0001437749-22-008091 · rdgdoc.xml · nonDerivative · entry 1 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,537 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 21:59 UTC | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | Exercise / conversionRestricted Stock Units · Derivative | 1,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-025538 · rdgdoc.xml · derivative · entry 2 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,430 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of ORA common stock upon vesting. F2 · derivative.exercise_date: This portion of Restricted Stock Units vested on November 4, 2021, the one-year anniversary of the date of grant. F2 · derivative.expiration_date: This portion of Restricted Stock Units vested on November 4, 2021, the one-year anniversary of the date of grant. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 21:59 UTC | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | Exercise / conversionCommon Stock | 1,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-025538 · rdgdoc.xml · nonDerivative · entry 1 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 21:59 UTC | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | GrantRestricted Stock Units · Derivative | 1,581 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-025538 · rdgdoc.xml · derivative · entry 3 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,581 Underlying: Common Stock · 1,581 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of ORA common stock upon vesting. F3 · derivative.exercise_date: This portion of Restricted Stock Units will vest (100%) on November 3, 2022, the one-year anniversary of the date of grant. F3 · derivative.expiration_date: This portion of Restricted Stock Units will vest (100%) on November 3, 2022, the one-year anniversary of the date of grant. Read SEC document |
| November 07, 2020 Filed Nov 9, 2020 14:03 UTC | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | Exercise / conversionRestricted Stock Units · Derivative | 1,256 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-023113 · rdgdoc.xml · derivative · entry 2 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,256 shares Expires 2020-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units (The "RSUs") vested on November 7, 2020, the one-year anniversary of the date of grant. F1 · derivative.exercise_date: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units (The "RSUs") vested on November 7, 2020, the one-year anniversary of the date of grant. F1 · derivative.expiration_date: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units (The "RSUs") vested on November 7, 2020, the one-year anniversary of the date of grant. Read SEC document |
| November 07, 2020 Filed Nov 9, 2020 14:03 UTC | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | Exercise / conversionCommon Stock | 1,256 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-023113 · rdgdoc.xml · nonDerivative · entry 1 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,607 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units (The "RSUs") vested on November 7, 2020, the one-year anniversary of the date of grant. F1 · price: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units (The "RSUs") vested on November 7, 2020, the one-year anniversary of the date of grant. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 11:13 UTC | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | GrantStock Appreciation right · Derivative | 1,315 | $0.00 Strike: $67.54 | $0.00 |
DisclosureSEC source: 0001437749-20-022859 · rdgdoc.xml · derivative · entry 2 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,315 Underlying: Common Stock · 1,315 shares Expires 2026-11-04 F3 · derivative.exercise_date: The stock appreciation rights vest 100% on November 4, 2021, the one-year anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights vest 100% on November 4, 2021, the one-year anniversary of the date of grant. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 11:13 UTC | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | GrantRestricted Stock Units · Derivative | 1,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-022859 · rdgdoc.xml · derivative · entry 1 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,430 Underlying: Common Stock · 1,430 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. F2 · derivative.exercise_date: The restricted stock units (The "RSUs") will vest (100%) on November 4, 2021, the one-year anniversary of the date of Grant. F2 · derivative.expiration_date: The restricted stock units (The "RSUs") will vest (100%) on November 4, 2021, the one-year anniversary of the date of Grant. Read SEC document |
| March 09, 2020 Filed Mar 18, 2020 13:52 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOptions · Derivative | 12,719 | Not disclosed Strike: $3.53 | Not disclosed |
DisclosureSEC source: 0001209191-20-019905 · doc4.xml · derivative · entry 6 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 12,719 shares Expires 2030-02-27 F5 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F8 · derivative.exercise_date: The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending February 27, 2021. Read SEC document |
| March 09, 2020 Filed Mar 18, 2020 13:52 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOptions · Derivative | 24,947 | Not disclosed Strike: $5.06 | Not disclosed |
DisclosureSEC source: 0001209191-20-019905 · doc4.xml · derivative · entry 5 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 24,947 shares Expires 2028-05-08 F5 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F7 · derivative.exercise_date: The ordinary shares underlying these options vested over a 12 month period, in equal, quarterly installments, ending May 8, 2019. Read SEC document |
| March 09, 2020 Filed Mar 18, 2020 13:52 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOptions · Derivative | 21,562 | Not disclosed Strike: $4.76 | Not disclosed |
DisclosureSEC source: 0001209191-20-019905 · doc4.xml · derivative · entry 4 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 21,562 shares Expires 2027-07-13 F5 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F6 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on July 13, 2017 and 6.25% every three months thereafter) ending July 13, 2021. Read SEC document |
| March 09, 2020 Filed Mar 18, 2020 13:52 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOptions · Derivative | 27,000 | Not disclosed Strike: $5.88 | Not disclosed |
DisclosureSEC source: 0001209191-20-019905 · doc4.xml · derivative · entry 3 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 27,000 shares Expires 2024-12-29 F5 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F4 · derivative.exercise_date: The Options vested over a period of three years from December 29, 2014 (33.3% on each anniversary of such date). Read SEC document |
| March 09, 2020 Filed Mar 18, 2020 13:52 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOrdinary Shares | 21,212 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-019905 · doc4.xml · nonDerivative · entry 2 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: Represents Foamix restricted stock unit awards ("Foamix RSUs") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an "Adjusted RSU Award") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR. Read SEC document |
| March 09, 2020 Filed Mar 18, 2020 13:52 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOrdinary Shares | 21,147 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-019905 · doc4.xml · nonDerivative · entry 1 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,212 F1 · price: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2) F2 · price: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement. Read SEC document |
| February 27, 2020 Filed Mar 3, 2020 21:36 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | GrantOptions · Derivative | 12,719 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001209191-20-015222 · doc4.xml · derivative · entry 2 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,719 Underlying: Ordinary Shares · 12,719 shares Expires 2030-02-27 F3 · security: Each option represents a contingent right to purchase one ordinary share of the issuer. F4 · derivative.exercise_date: The ordinary shares underlying this option award vest over a 12 month period, in equal, quarterly installments, ending February 27, 2021. Read SEC document |
| February 27, 2020 Filed Mar 3, 2020 21:36 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | GrantOrdinary Shares | 14,164 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015222 · doc4.xml · nonDerivative · entry 1 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,359 F1 · security: This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. F2 · shares: The ordinary shares underlying this restricted share unit award vest over a 12 month period, in equal, quarterly installments, ending February 27, 2021. Read SEC document |
| November 07, 2019 Filed Nov 9, 2019 02:34 UTC | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | GrantStock Appreciation right · Derivative | 1,210 | $0.00 Strike: $76.87 | $0.00 |
DisclosureSEC source: 0001437749-19-022225 · rdgdoc.xml · derivative · entry 4 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,210 Underlying: Common Stock · 1,210 shares Expires 2025-11-06 F3 · derivative.exercise_date: The stock appreciation rights vest 100% on the one-year anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights vest 100% on the one-year anniversary of the date of grant. Read SEC document |
| November 07, 2019 Filed Nov 9, 2019 02:34 UTC | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | GrantRestricted Stock Units · Derivative | 1,256 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-022225 · rdgdoc.xml · derivative · entry 3 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,256 Underlying: Common Stock · 1,256 shares Expires 2020-11-07 F2 · derivative.exercise_price: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units (The "RSUs") will vest (100%) on November 7, 2020, one-year anniversary of the date of grant. F2 · derivative.exercise_date: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units (The "RSUs") will vest (100%) on November 7, 2020, one-year anniversary of the date of grant. F2 · derivative.expiration_date: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units (The "RSUs") will vest (100%) on November 7, 2020, one-year anniversary of the date of grant. Read SEC document |
| November 07, 2019 Filed Nov 9, 2019 02:34 UTC | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | Exercise / conversionRestricted Stock Units · Derivative | 1,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-022225 · rdgdoc.xml · derivative · entry 2 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,825 shares Expires 2019-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units vested on November 7, 2019, the one-year anniversary of the date of grant. F1 · derivative.exercise_date: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units vested on November 7, 2019, the one-year anniversary of the date of grant. F1 · derivative.expiration_date: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units vested on November 7, 2019, the one-year anniversary of the date of grant. Read SEC document |
| November 07, 2019 Filed Nov 9, 2019 02:34 UTC | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | Exercise / conversionCommon Stock | 1,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-022225 · rdgdoc.xml · nonDerivative · entry 1 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units vested on November 7, 2019, the one-year anniversary of the date of grant. F1 · price: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units vested on November 7, 2019, the one-year anniversary of the date of grant. Read SEC document |
| November 07, 2019 Filed Nov 12, 2019 21:14 UTC Amendment | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | GrantStock Appreciation right · Derivative | 1,210 | $0.00 Strike: $76.87 | $0.00 |
DisclosureSEC source: 0001437749-19-022474 · rdgdoc.xml · derivative · entry 4 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,210 Underlying: Common Stock · 1,210 shares Expires 2025-11-06 F4 · shares: The Reporting Person is amending the Form 4 filed on November 8, 2019, which, due to administrative error, inadvertently reported grants of 1,256 restricted stock units and 1,210 stock appreciation rights as dispositions rather than acquisitions. F3 · derivative.exercise_date: The stock appreciation rights vest 100% on the one-year anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights vest 100% on the one-year anniversary of the date of grant. Read SEC document |
| November 07, 2019 Filed Nov 12, 2019 21:14 UTC Amendment | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | GrantRestricted Stock Units · Derivative | 1,256 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-022474 · rdgdoc.xml · derivative · entry 3 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,256 Underlying: Common Stock · 1,256 shares Expires 2020-11-07 F2 · derivative.exercise_price: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units (The "RSUs") will vest (100%) on November 7, 2020, one-year anniversary of the date of grant. F4 · shares: The Reporting Person is amending the Form 4 filed on November 8, 2019, which, due to administrative error, inadvertently reported grants of 1,256 restricted stock units and 1,210 stock appreciation rights as dispositions rather than acquisitions. F2 · derivative.exercise_date: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units (The "RSUs") will vest (100%) on November 7, 2020, one-year anniversary of the date of grant. F2 · derivative.expiration_date: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units (The "RSUs") will vest (100%) on November 7, 2020, one-year anniversary of the date of grant. Read SEC document |
| November 07, 2019 Filed Nov 12, 2019 21:14 UTC Amendment | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | Exercise / conversionRestricted Stock Units · Derivative | 1,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-022474 · rdgdoc.xml · derivative · entry 2 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,825 shares Expires 2019-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units vested on November 7, 2019, the one-year anniversary of the date of grant. F1 · derivative.exercise_date: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units vested on November 7, 2019, the one-year anniversary of the date of grant. F1 · derivative.expiration_date: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units vested on November 7, 2019, the one-year anniversary of the date of grant. Read SEC document |
| November 07, 2019 Filed Nov 12, 2019 21:14 UTC Amendment | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | Exercise / conversionCommon Stock | 1,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-022474 · rdgdoc.xml · nonDerivative · entry 1 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units vested on November 7, 2019, the one-year anniversary of the date of grant. F1 · price: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units vested on November 7, 2019, the one-year anniversary of the date of grant. Read SEC document |
| May 16, 2019 Filed Jul 8, 2019 20:50 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | GrantOrdinary Shares | 28,195 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-041422 · doc4.xml · nonDerivative · entry 1 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,195 F1 · security: This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. F2 · shares: The ordinary shares underlying this restricted share unit award vest over a 12 month period, in equal, quarterly installments, ending May 16, 2020. Read SEC document |
| November 07, 2018 Filed Nov 8, 2018 22:27 UTC | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | GrantStock Appreciation right · Derivative | 1,621 | $0.00 Strike: $53.16 | $0.00 |
DisclosureSEC source: 0001437749-18-020108 · rdgdoc.xml · derivative · entry 4 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,621 Underlying: Common Stock · 1,621 shares Expires 2024-11-07 F3 · derivative.exercise_date: The stock appreciation rights vest 100% on the one-year anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights vest 100% on the one-year anniversary of the date of grant. Read SEC document |
| November 07, 2018 Filed Nov 8, 2018 22:27 UTC | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | GrantRestricted Stock Units · Derivative | 1,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-18-020108 · rdgdoc.xml · derivative · entry 3 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,825 Underlying: Common Stock · 1,825 shares Expires 2018-11-07 F2 · derivative.exercise_price: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units (The "RSUs") will vest (100%) on November 7, 2019, one-year anniversary of the date of grant. F2 · derivative.exercise_date: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units (The "RSUs") will vest (100%) on November 7, 2019, one-year anniversary of the date of grant. F2 · derivative.expiration_date: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units (The "RSUs") will vest (100%) on November 7, 2019, one-year anniversary of the date of grant. Read SEC document |
| November 07, 2018 Filed Nov 8, 2018 22:27 UTC | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | Exercise / conversionRestricted Stock Units · Derivative | 1,526 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-18-020108 · rdgdoc.xml · derivative · entry 2 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,526 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units vested on November 7, 2018, the one-year anniversary of the date of grant. F1 · derivative.exercise_date: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units vested on November 7, 2018, the one-year anniversary of the date of grant. F1 · derivative.expiration_date: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units vested on November 7, 2018, the one-year anniversary of the date of grant. Read SEC document |
| November 07, 2018 Filed Nov 8, 2018 22:27 UTC | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | Exercise / conversionCommon Stock | 1,526 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-18-020108 · rdgdoc.xml · nonDerivative · entry 1 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units vested on November 7, 2018, the one-year anniversary of the date of grant. F1 · price: Each restricted stock unit represent the right to receive per share of ORA common stock upon vesting. The restricted stock units vested on November 7, 2018, the one-year anniversary of the date of grant. Read SEC document |
| May 08, 2018 Filed May 10, 2018 21:27 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | GrantOptions · Derivative | 24,947 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0001178913-18-001596 · zk1821660.xml · derivative · entry 1 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,947 Underlying: Ordinary Shares · 24,947 shares Expires 2028-05-08 F1 · security: Each option represents a contingent right to purchase one ordinary share of the issuer. F2 · derivative.exercise_date: The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending May 8, 2019. Read SEC document |
| November 07, 2017 Filed Nov 10, 2017 02:42 UTC | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | GrantStock Appreciation Rights · Derivative | 1,361 | $0.00 Strike: $63.35 | $0.00 |
DisclosureSEC source: 0001437749-17-018985 · rdgdoc.xml · derivative · entry 2 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,887 Underlying: Common Stock · 1,361 shares Expires 2023-11-07 F3 · derivative.exercise_date: The stock appreciation rights vest 100% on the one year anniversary of the date of grant. Read SEC document |
| November 07, 2017 Filed Nov 10, 2017 02:42 UTC | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | GrantRestricted Stock Units · Derivative | 1,526 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-17-018985 · rdgdoc.xml · derivative · entry 1 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,526 Underlying: Common Stock · 1,526 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of ORA common stock upon vesting. F2 · derivative.exercise_date: The restricted stock units vest 100% on the one year anniversary of the date of grant. F2 · derivative.expiration_date: The restricted stock units vest 100% on the one year anniversary of the date of grant. Read SEC document |
| November 07, 2016 Filed Nov 9, 2016 22:01 UTC | ORMAT TECHNOLOGIES, INC. ORA · Entity 3743 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $47.46 | $0.00 |
DisclosureSEC source: 0001437749-16-041601 · rdgdoc.xml · derivative · entry 1 STERN STANLEY · CIK 0001098567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 7,500 shares Expires 2023-11-08 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.